Smartag Trademark Details
Word Mark | Smartag |
---|---|
Status | Alive 819 — Su - Registration Review Complete |
Current Owner
Catalent Pharma Solutions, Inc. of Somerset, NJ
View all trademarks for Catalent Pharma Solutions, Inc.Serial Number | 85963028 |
---|---|
Status Date | Tuesday, August 30, 2016 |
Filing Date | Tuesday, August 30, 2016 |
Attorney | Vanessa A. Ignacio, |
Correspondent
VANESSA A. IGNACIO,
LOWENSTEIN SANDLER LLP
65 LIVINGSTON AVE
ROSELAND, NJ 07068-1725
LOWENSTEIN SANDLER LLP
65 LIVINGSTON AVE
ROSELAND, NJ 07068-1725
Case File Statements
Goods & Services | Chemical, biochemical and biological reagents in the nature of or used to create or improve antibody-drug conjugates or any protein conjugated to a drug, poly nucleotide, another protein, chemical, or other functional entity used in industry and science; chemicals for use in bioconjugation, reversible bioconjugation, irreversible bioconjugation, reversible cysteine protection, surface modification, and prodrug production for scientific use; biochemicals, namely, polypeptides, polypeptides for in vivo applications, polypeptides for in vitro applications, polynucleic acids, polynucleic acids for in vivo applications, and polynucleic acids for in vitro applications for scientific use; biomolecules, namely, proteins, peptides, antibodies, antibody fragments, antibody mimetic proteins, and polynucleic acids for scientific use; chemical products for diagnostic use, namely, conjugates of polypeptides with small molecule drugs, imaging agents, flourocromes and radiolabels for medical research applications; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in basic scientific research and development, medical research; diagnostic preparations for scientific or research use in connection with antibody drug conjugates; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system |
---|---|
Goods & Services | Pharmaceutical preparations for the prevention or treatment of human diseases, namely, diseases of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; chemical, biological and biochemical preparations for medical and pharmaceutical purposes, namely, antibody-drug conjugates or any protein conjugated to a drug, poly nucleotide, another protein, chemical, or other functional entity or such preparations used as linker or payload molecules therein used to treat cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; pharmaceutical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; biological preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; diagnostic preparations for medical purposes in connection with the diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; antibody preparations, namely, antibody or protein bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system, including antibody/protein-drug conjugates, antibody/protein-radiolabled conjugates and antibody/protein-imaging agent conjugates; chemical products for medical diagnostic use, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; biochemical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system |
Pseudo Mark | Smar Tag |
Classifications
International Class Codes |
001
|
---|---|
U.S. Class Codes | 001, 005, 006, 010, 026, 046 |
Status | 6 — Active |
Status Date | Thursday, June 27, 2013 |
First Use Anywhere | Monday, October 20, 2014 |
First Use In Commerce | Monday, October 20, 2014 |
Primary Code | 001 |
International Class Codes |
005
|
---|---|
U.S. Class Codes | 006, 018, 044, 046, 051, 052 |
Status | 6 — Active |
Status Date | Thursday, June 27, 2013 |
First Use Anywhere | Monday, October 20, 2014 |
First Use In Commerce | Monday, October 20, 2014 |
Primary Code | 005 |
Trademark Timeline
-
Jun 18 2013Trademark application filed with USPTO
-
Jun 21 2013New Application Entered In Tram
-
Jun 27 2013New Application Office Supplied Data Entered In Tram
-
Jun 28 2013Notice of Pseudo Mark E-Mailed
-
Sep 10 2013Assigned To Examiner
-
Sep 16 2013Notification of Non-Final Action E-Mailed
-
Sep 16 2013Non-Final Action E-Mailed
-
Sep 16 2013Non-Final Action Written
-
Mar 10 2014Correspondence Received In Law Office
-
Mar 10 2014Teas Response To Office Action Received
-
Mar 11 2014Teas/email Correspondence Entered
-
Apr 02 2014Notification of Non-Final Action E-Mailed
-
Apr 02 2014Non-Final Action E-Mailed
-
Apr 02 2014Non-Final Action Written
-
Sep 17 2014Teas/email Correspondence Entered
-
Sep 17 2014Correspondence Received In Law Office
-
Sep 17 2014Teas Response To Office Action Received
-
Oct 09 2014Approved For Pub - Principal Register
-
Oct 20 2014First use anywhere for the mark
-
Oct 20 2014First use in commerce for the mark
-
Oct 20 2014First use anywhere for the mark
-
Oct 20 2014First use in commerce for the mark
-
Oct 28 2014Law Office Publication Review Completed
-
Oct 28 2014Assigned To Lie
-
Nov 12 2014Notification of Notice of Publication E-Mailed
-
Dec 02 2014Official Gazette Publication Confirmation E-Mailed
-
Dec 02 2014Published For Opposition
-
Dec 23 2014Extension of Time To Oppose Received
-
Jun 16 2015Extension of Time To Oppose Process - Terminated
-
Jul 16 2015Teas Post Publication Amendment Received
-
Jul 22 2015Assigned To Petition Staff
-
Jul 25 2015Applicant Supplied Changes/corrections After Pub Approval Not Ent
-
Jul 28 2015Noa E-Mailed - Sou Required From Applicant
-
Aug 04 2015Teas Petition To Director Received
-
Aug 31 2015Assigned To Petition Staff
-
Sep 02 2015Petition To Director - Granted
-
Jan 15 2016Extension 1 Granted
-
Jan 15 2016Extension 1 Filed
-
Jan 15 2016Teas Extension Received
-
Jan 19 2016Notice of Approval of Extension Request E-Mailed
-
Jul 13 2016Use Amendment Filed
-
Jul 13 2016Teas Statement of Use Received
-
Aug 06 2016Case Assigned To Intent To Use Paralegal
-
Aug 09 2016Statement of Use Processing Complete
-
Aug 30 2016Allowed Principal Register - Sou Accepted
-
Aug 31 2016Notice of Acceptance of Statement of Use E-Mailed